BCIQ Profiles

Company Profile Report
1223 Deals QTs
BioCentury & Getty Images


Dec. 21-23 Deals Quick Takes: Cytokinetics regains European rights to heart failure program; plus Boehringer-Epizyme, Vertex-Skyhawk, Lilly-Prevail, GSK-Sosei Heptares, ImmunityBio-NantKwest and more

Dec 22, 2020 | 11:24 PM GMT

Cytokinetics regains European rights from Servier to heart failure program
Cytokinetics Inc. (NASDAQ:CYTK) regained European rights to heart failure treatment omecamtiv mecarbil from Servier. The deal termination comes a month after Amgen Inc. (NASDAQ:AMGN) returned its rights to the cardiac myosin activator. In October, omecamtiv mecarbil led to a statistically significant reduction in

Read the full 846 word article

How to gain access

Continue reading with a
two-week free trial.